Pharma Tech

IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib

Aug 3, 2026, 9:29 AM

Read Full Article → IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib

Translate article text

Choose a language and wait for the translated text.

IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to $488.3m, giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.